GlassScriptPhysician profile
Kanchan Parasher
NPI 1922184381
$1,579.68
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $366 · 2021: $467 · 2022: $217 · 2023: $68.93 · 2024: $90.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $290.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.42 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $176.78 | 2019-2022 | |
| Novo Nordisk INC | $151.47 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $116.97 | 2019-2022 | |
| Amgen INC. | $105.12 | 2019-2022 | |
| Stimwave Technologies Incorporated | $71.90 | 2019 | |
| Dexcom, INC. | $61.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $59.63 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $54.25 | 2023 | |
| Amarin Pharma, INC. | $46.04 | 2021 | |
| Almatica Pharma LLC | $37.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.16 | 2022 | |
| Eisai INC. | $18.87 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $16.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.50 | 2022 | |
| Genentech USA, INC. | $13.79 | 2021 | |
| Redhill Biopharma INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanchan Parasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.